vs
Guardant Health, Inc.（GH）与PROCORE TECHNOLOGIES, INC.（PCOR）财务数据对比。点击上方公司名可切换其他公司
PROCORE TECHNOLOGIES, INC.的季度营收约是Guardant Health, Inc.的1.3倍（$359.3M vs $281.3M），PROCORE TECHNOLOGIES, INC.净利率更高（-2.5% vs -45.7%，领先43.2%），Guardant Health, Inc.同比增速更快（39.4% vs 15.7%），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 12.4%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
Procore Technologies是2002年成立的美国建筑管理软件即服务（SaaS）企业，总部位于加利福尼亚州卡平特里亚。公司打造的全球平台可连接建筑行业从业者，支持搭建简化工作流，统一展现建筑项目信息，覆盖任务追踪、项目流程管理、日程排期等核心功能。
GH vs PCOR — 直观对比
营收规模更大
PCOR
是对方的1.3倍
$281.3M
营收增速更快
GH
高出23.7%
15.7%
净利率更高
PCOR
高出43.2%
-45.7%
两年增速更快
GH
近两年复合增速
12.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $359.3M |
| 净利润 | $-128.5M | $-9.1M |
| 毛利率 | 64.6% | 80.1% |
| 营业利润率 | -43.0% | 15.5% |
| 净利率 | -45.7% | -2.5% |
| 营收同比 | 39.4% | 15.7% |
| 净利润同比 | -15.8% | 72.4% |
| 每股收益（稀释后） | $-1.01 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHPCOR
| Q1 26 | — | $359.3M | ||
| Q4 25 | $281.3M | $349.1M | ||
| Q3 25 | $265.2M | $338.9M | ||
| Q2 25 | $232.1M | $323.9M | ||
| Q1 25 | $203.5M | $310.6M | ||
| Q4 24 | $201.8M | $302.0M | ||
| Q3 24 | $191.5M | $295.9M | ||
| Q2 24 | $177.2M | $284.3M |
净利润GHPCOR
| Q1 26 | — | $-9.1M | ||
| Q4 25 | $-128.5M | $-37.6M | ||
| Q3 25 | $-92.7M | $-9.1M | ||
| Q2 25 | $-99.9M | $-21.1M | ||
| Q1 25 | $-95.2M | $-33.0M | ||
| Q4 24 | $-111.0M | $-62.3M | ||
| Q3 24 | $-107.8M | $-26.4M | ||
| Q2 24 | $-102.6M | $-6.3M |
毛利率GHPCOR
| Q1 26 | — | 80.1% | ||
| Q4 25 | 64.6% | 80.1% | ||
| Q3 25 | 64.7% | 79.7% | ||
| Q2 25 | 65.0% | 79.1% | ||
| Q1 25 | 63.3% | 79.1% | ||
| Q4 24 | 61.6% | 81.2% | ||
| Q3 24 | 61.1% | 81.4% | ||
| Q2 24 | 59.1% | 83.1% |
营业利润率GHPCOR
| Q1 26 | — | 15.5% | ||
| Q4 25 | -43.0% | -12.3% | ||
| Q3 25 | -37.3% | -4.4% | ||
| Q2 25 | -45.9% | -9.3% | ||
| Q1 25 | -54.6% | -11.7% | ||
| Q4 24 | -62.4% | -21.9% | ||
| Q3 24 | -61.3% | -12.3% | ||
| Q2 24 | -56.8% | -5.2% |
净利率GHPCOR
| Q1 26 | — | -2.5% | ||
| Q4 25 | -45.7% | -10.8% | ||
| Q3 25 | -35.0% | -2.7% | ||
| Q2 25 | -43.0% | -6.5% | ||
| Q1 25 | -46.8% | -10.6% | ||
| Q4 24 | -55.0% | -20.6% | ||
| Q3 24 | -56.3% | -8.9% | ||
| Q2 24 | -57.9% | -2.2% |
每股收益（稀释后）GHPCOR
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $-1.01 | $-0.25 | ||
| Q3 25 | $-0.74 | $-0.06 | ||
| Q2 25 | $-0.80 | $-0.14 | ||
| Q1 25 | $-0.77 | $-0.22 | ||
| Q4 24 | $-0.90 | $-0.42 | ||
| Q3 24 | $-0.88 | $-0.18 | ||
| Q2 24 | $-0.84 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $386.0M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $-99.3M | $1.2B |
| 总资产 | $2.0B | $2.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHPCOR
| Q1 26 | — | $386.0M | ||
| Q4 25 | $378.2M | $768.5M | ||
| Q3 25 | $580.0M | $684.0M | ||
| Q2 25 | $629.1M | $620.9M | ||
| Q1 25 | $698.6M | $566.7M | ||
| Q4 24 | $525.5M | $775.4M | ||
| Q3 24 | $585.0M | $756.9M | ||
| Q2 24 | $933.7M | $735.4M |
总债务GHPCOR
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益GHPCOR
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-99.3M | $1.3B | ||
| Q3 25 | $-354.5M | $1.2B | ||
| Q2 25 | $-305.5M | $1.2B | ||
| Q1 25 | $-250.8M | $1.2B | ||
| Q4 24 | $-139.6M | $1.3B | ||
| Q3 24 | $-60.1M | $1.3B | ||
| Q2 24 | $-1.6M | $1.3B |
总资产GHPCOR
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.0B | $2.2B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.3B | $2.0B | ||
| Q1 25 | $1.3B | $1.9B | ||
| Q4 24 | $1.5B | $2.1B | ||
| Q3 24 | $1.5B | $2.0B | ||
| Q2 24 | $1.6B | $2.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $76.8M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | — |
| 自由现金流率自由现金流/营收 | -19.3% | — |
| 资本支出强度资本支出/营收 | 9.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-233.1M | — |
8季度趋势，按日历期对齐
经营现金流GHPCOR
| Q1 26 | — | $76.8M | ||
| Q4 25 | $-26.4M | $114.9M | ||
| Q3 25 | $-35.4M | $88.5M | ||
| Q2 25 | $-60.3M | $30.8M | ||
| Q1 25 | $-62.7M | $66.0M | ||
| Q4 24 | $-64.5M | $29.1M | ||
| Q3 24 | $-51.1M | $39.3M | ||
| Q2 24 | $-94.0M | $58.7M |
自由现金流GHPCOR
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $109.2M | ||
| Q3 25 | $-45.8M | $83.1M | ||
| Q2 25 | $-65.9M | $27.9M | ||
| Q1 25 | $-67.1M | $62.0M | ||
| Q4 24 | $-83.4M | $17.4M | ||
| Q3 24 | $-55.3M | $35.7M | ||
| Q2 24 | $-99.1M | $56.8M |
自由现金流率GHPCOR
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | 31.3% | ||
| Q3 25 | -17.3% | 24.5% | ||
| Q2 25 | -28.4% | 8.6% | ||
| Q1 25 | -33.0% | 20.0% | ||
| Q4 24 | -41.3% | 5.8% | ||
| Q3 24 | -28.9% | 12.1% | ||
| Q2 24 | -55.9% | 20.0% |
资本支出强度GHPCOR
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 1.6% | ||
| Q3 25 | 3.9% | 1.6% | ||
| Q2 25 | 2.4% | 0.9% | ||
| Q1 25 | 2.2% | 1.3% | ||
| Q4 24 | 9.4% | 3.9% | ||
| Q3 24 | 2.2% | 1.2% | ||
| Q2 24 | 2.9% | 0.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PCOR
暂无分部数据
